Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.


Sector Spotlight

Taking a Profit (or Two) on Large-Cap Tech

Last summer I recommended buying LEAPS, or long-term call options, on Broadcom (NSDQ: AVGO) and Lam Research (NSDQ: LRCX). At the time, both stocks appeared undervalued, according to my IDEAL stock-rating system, and since then each has appreciated roughly 40%, confirming my analysis. I still like both companies, but I am going to close out […]

Our Successful Bet on Companies Analysts Overlook

Of the three under-followed stocks we chose, only one faltered, leaving us with a total 43% gain.

Small Biotech, an Endangered Species

The Republican healthcare plan was the last straw for two struggling biotech holdings.

Cashing In On Private Cash

Fundrise gives small investors access to private real estate deals         and may be a great investment itself.

Big Bills Are Big Business

This company rakes in the bucks by making money safer.

Bristol-Myers: Pragmatic, Profitable

Now a value stock, this big pharma is managing its current drugs and its pipeline to perfection.

Do You Hear (Robot) Footsteps?

A machine may be after your job; if you can’t beat it, own it.

This Firm Turns Fewer Doctor Visits Into Profits

Bio Telemetry transforms cardiac care with a patient’s cellphone.

Fishing in a Swamp

The pool of MLP preferred issues is small and treacherous, but we did find one keeper.

Insurers’ Secret Weapon

“Trumpcare” will unlock a bag of goodies for the Big Five.

Page 1 of 2112345...Last »